Title

Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics
Multi-dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Status

    Unknown status
  • Study Participants

    800
Major Depressive Disorder is one of the most common mental diseases,which increases health-care costs and the financial burden to families and societies. Considering its complex clinical symptoms and diversity of comorbidity, depressive disorder's recognition,diagnosis,and antihistone are based on symptomatology,which is lack of multidimensional diagnosis technique based on clinical pathological characteristics,as well as lack of individualized therapy strategy based on quantified evaluation. Besides, other physical diseases,such as nervous system diseases, cardiovascular diseases,endocrine diseases, have the high comorbidity of depressive disorder. However,there is no precise diagnosis technique or standardized therapy strategy. With all those taken into consideration,our study is aimed to adopt E-mental health and m-Health to explore multi-dimensional diagnosis, individualized therapy and management technique based on molecular biology,nerve electrophysiology,and neuroimaging technology etc.
Four parts included in our study:

Part 1:The research, development and verification of indicators based on biomarkers and clinical characteristics to guide the diagnosis and treatment of depressive disorders

to screen biomarkers, to explore its pathophysiology, and to analyze the correlation between clinical subtypes/characteristics and biomarkers.
To differentiate the subtypes of depressive disorder(depression/underload, atypical, anxiety/somatization) based on clinical symptoms and clinical assessement.
To establish personalized therapy strategies,and to explore tool kits for diagnosis and treatment based on biomarkers and clinical characteristics.
to choose appropriate indicators to monitor therapy and side effect by collecting and analyzing blood/imaging/neuropsychological data.

Part 2: The development,transition and application of hierarchical model diagnostic technique for physical diseases combined with depressive disorder.

to recruit patients with physical diseases combined with depressive disorder, and explore potential biomarkers.
To chose appropriate therapy strategies based on measurement based care(MBC), providing hierarchical model diagnostic technique for patients.
To weigh therapy efficiency and adverse effect among different medicine therapy groups.

Part3: The development and application of comprehensive prevention, diagnosis,and intervention model of depressive disorder.

To explore and establish online screening and assistant diagnosis system for patients with depressive disorder.
research ,development and application of intelligent e-MBC. Part 4: The development,transition and application of e-MBC sharing platform.
Study Started
Aug 01
2017
Primary Completion
Dec 31
2019
Anticipated
Study Completion
Dec 31
2020
Anticipated
Last Update
Oct 10
2017

Drug Fluoxetine

Fluoxetine is one kind of selective serotonin reuptake inhibitor(SSRIs), whose effect is much better than other non-underload subtypes compared with underload subtypes.So patients would be treated with fluoxetine only.

Combination Product fluoxetine + cognitive-behavioral treatment(CBT)

the investigators would recommend fluoxetine to help to cure depressive disorder.And CBT is a very effective way for patients to alleviate or relieve clinical symptoms during episode stage.

Drug fluoxetine + Amfebutamone [fluoxetine (prozac), amfebutamone]

Amfebutamone is one kind of SNRIs, and it shows much better therapy effect on patients with exhaustion /dizziness.So the investigators recommend these two drugs to help to cure patients with depressive disorder.

Combination Product physical treatment+fluoxetine+amfebutamone [fluoxetine (prozac), amfebutamone]

the investigators recommend drug(fluoxetine and amfebutamone) and physical treatment as intervention.

Drug Fluvoxamine

Fluvoxamine could inhibit CYP1A2 and CYP2C19 and affect the metabolism of melatonin, and help to release symptoms of depressive disorder with sleep problems.

Drug Lithium+fluvoxamine [fluvoxamine (luvox), lithium (lithonate)]

the investigators recommend lithium as a mood stabilizer and use fluvoxamine to affect the level of melatonin.

Combination Product fluvoxamine + lithium + physical therapy [fluvoxamine (luvox), lithium (lithonate)]

the investigators recommend depressants and mood stabilizers as well as physical therapy to help to cure depressive disorder.

Combination Product Cognitive behavior treatment +fluvoxamine

the investigators recommend behavioral therapy as well as drugs.

Drug Mirtazapine/SNRIs

Mirtazapine is one kind of antagonist of a2 adrenergic receptors and could block 5-hydroxytryptamine2 and 5-hydroxytryptamine3,help to release symptoms like anxiety or somatization.Besides, SNRIs could also make similar effect on patients.Therefore, the investigators recommend mirtazapine/SNRIs to treat patients with depressive disorder.

Combination Product mirtazapine+ Cognitive behavior treatment

the investigators recommend CBT and mirtazapine as interventions.The dosage and frequency would depend on patients' severity of symptoms .

Drug mirtazapine + SNRIs

the investigator recommend mirtazapine and SNRIs to treat patients with major depressive disorder.

Combination Product mirtazapine + SNRIs + physical therapy

the investigators would manage to use drugs and physical treatment to help to release the symptoms of depressive disorder.

Other TAU(treat as usual)

patients in this group would receive therapy strategies according to their symptoms and preference.

Depression/underload 1 Experimental

This group would be treated with fluoxetine from the minimum dosage.

Depression/underload 2 Experimental

This group would be treated with fluoxetine combined with cognitive behavior treatment

Depression/underload 3 Experimental

This group would be treated with fluoxetine and amfebutamone from the minimum dosage.

Depression/underload 4 Experimental

This group would be treated with fluoxetine + physical treatment to help to cure depressive disorder.

Atypical 1 Experimental

This group would be treated with fluvoxamine from the minimum dosage.

Atypical 2 Experimental

This group would be treated with fluoxetine + cognitive behavior treatment

Atypical 3 Experimental

This group would be treated with fluvoxamine + lithium from the minimum dosage.

Atypical 4 Experimental

This group would be treated with fluvoxamine + lithium + physical treatment

Anxiety/somatization 1 Experimental

This group would be treated with mirtazapine/selective serotonin-norepinephrine reuptake inhibitors(SNRIs) from the minimum dosage.

Anxiety/somatization 2 Experimental

This group would be treated with mirtazapine/SNRIs + cognitive behavior treatment.

Anxiety/somatization 3 Experimental

This group would be treated with mirtazapine + SNRIs from the minimum dosage.

Anxiety/somatization 4 Experimental

This group would be treated with mirtazapine + SNRIs + physical treatment.

treatment as usual(TAU) Experimental

The investigators recommend therapy strategies according to accessible methods.

Criteria

Inclusion Criteria:

aged 18-65 years;
clinical diagnosis of major depressive disorder;
17-Hamilton Depression Scale>20;
14-Hamilton Anxiety Scale score<7;
outpatient treatment;
first episode;
medication-naive;

Exclusion Criteria:

clinical diagnosis of schizophrenia, schizoaffective disorder;
any prescription or psychotropic medications in the past 4 week;
serious medical or neurological illness;
current pregnancy or breastfeeding.
No Results Posted